Literature DB >> 4055987

Pharmacokinetics of melatonin in man: first pass hepatic metabolism.

E A Lane, H B Moss.   

Abstract

Hepatic clearance concepts were applied to existing data on iv and oral administration of melatonin to man. A high hepatic extraction ratio was calculated, suggesting prominent first pass hepatic metabolism and reduced bioavailability for orally administered melatonin. Using clearance parameters and previous data, endogenous production rates for melatonin were determined for normal individuals and patients with cirrhosis. Normal melatonin production was 28.8 micrograms/day, while the production rate for cirrhotic patients was 12.3 micrograms/day. Thus, not only do cirrhotic patients have decreased melatonin elimination, as noted in the original report, but they also have decreased daily melatonin production.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055987     DOI: 10.1210/jcem-61-6-1214

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Pharmacokinetics of melatonin in preterm infants.

Authors:  Nazakat M Merchant; Denis V Azzopardi; Ahmed F Hawwa; James C McElnay; Benita Middleton; J Arendt; Tomoki Arichi; Pierre Gressens; A David Edwards
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

2.  Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction.

Authors:  Snehasis Jana; Himanshu Rastogi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

3.  Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults.

Authors:  Nalaka S Gooneratne; Alena Y Z Edwards; Chen Zhou; Norma Cuellar; Michael A Grandner; Jeffrey S Barrett
Journal:  J Pineal Res       Date:  2012-02-21       Impact factor: 13.007

4.  Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats.

Authors:  R Jayachandra Babu; Pankaj Patrick Dayal; Kasturi Pawar; Mandip Singh
Journal:  J Drug Target       Date:  2011-03-23       Impact factor: 5.121

Review 5.  Extrapineal melatonin: sources, regulation, and potential functions.

Authors:  Darío Acuña-Castroviejo; Germaine Escames; Carmen Venegas; María E Díaz-Casado; Elena Lima-Cabello; Luis C López; Sergio Rosales-Corral; Dun-Xian Tan; Russel J Reiter
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

6.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

7.  Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection.

Authors:  C Mallo; R Zaĭdan; G Galy; E Vermeulen; J Brun; G Chazot; B Claustrat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Urine melatonin in alcoholic patients: a marker of alcohol abuse?

Authors:  G Murialdo; U Filippi; P Costelli; S Fonzi; P Bo; A Polleri; F Savoldi
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

9.  Prolonged exposure of cholestatic rats to complete dark inhibits biliary hyperplasia and liver fibrosis.

Authors:  Yuyan Han; Paolo Onori; Fanyin Meng; Sharon DeMorrow; Julie Venter; Heather Francis; Antonio Franchitto; Debolina Ray; Lindsey Kennedy; John Greene; Anastasia Renzi; Romina Mancinelli; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-09-11       Impact factor: 4.052

10.  Dietary correlates of urinary 6-sulfatoxymelatonin concentrations in the Nurses' Health Study cohorts.

Authors:  Eva S Schernhammer; Diane Feskanich; Caroline Niu; Regina Dopfel; Michelle D Holmes; Susan E Hankinson
Journal:  Am J Clin Nutr       Date:  2009-08-12       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.